CH LEIDEN | Jotup

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Retrieved on:

Thursday, April 4, 2024

Safety, CIIC, Abstract, HAE, Hereditary angioedema, Conference, Bradykinin receptor B2, Pharmaceutical industry

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.

Key Points:

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.
Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
The posters and associated presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: https://ir.pharvaris.com/news-events/events-presentations .

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Retrieved on:

Monday, March 18, 2024

Angioedema, Conference, EOP, Attack, Quality of life (healthcare), Network, Safety, HAE, Hereditary angioedema, Patient, Adolescence, Heredity, Country, National Congress, Physician, Medicine, Pharmaceutical industry

“We are committed to the continued advancement of our clinical development program of deucrictibant to fulfill unmet needs of current HAE treatment,” said Berndt Modig, Chief Executive Officer of Pharvaris.

Key Points:

“We are committed to the continued advancement of our clinical development program of deucrictibant to fulfill unmet needs of current HAE treatment,” said Berndt Modig, Chief Executive Officer of Pharvaris.
The RAPIDe-3 study is designed to assess the effectiveness of deucrictibant in addressing that unmet need.
RAPIDe-3 is a randomized, double-blind, placebo-controlled, crossover study, which is designed to enroll approximately 120 adolescent and adult participants globally.
The data illustrates that HRQoL is negatively impacted, including functional and psychological impairment, in people with HAE.

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Retrieved on:

Wednesday, March 6, 2024

Bradykinin receptor B2, Hereditary angioedema, Real, Safety, Heredity, Treatment, Conference, HAE, Network, Abstract, National Congress, Pharmaceutical industry

ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) , to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas , to be held from March 15-17, 2024, in Panama City, Panama.

Key Points:

ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) , to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas , to be held from March 15-17, 2024, in Panama City, Panama.
Details of the presentations are as follows:
Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
2024 HAEi Regional Conference Americas, Panama City, Panama, March 15-17, 2024.
Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Title: Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Title: Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey
The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations .

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Retrieved on:

Tuesday, March 5, 2024

Fontainebleau Miami Beach, HAE, Hereditary angioedema, Conference

ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that its management will participate in the Leerink Global Biopharma Conference 2024, taking place from March 11-13, 2024, at the Fontainebleau Miami Beach, Miami.

Key Points:

ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that its management will participate in the Leerink Global Biopharma Conference 2024, taking place from March 11-13, 2024, at the Fontainebleau Miami Beach, Miami.
Details are as follows:
A live audio webcast will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .
The audio replay will be available on Pharvaris’ website for 30 days following the presentation.

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Retrieved on:

Thursday, February 22, 2024

CHAPTER-1 is a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and type 2 (HAE-1/2).

Key Points:

CHAPTER-1 is a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and type 2 (HAE-1/2).
34 participants were treated with double-blinded study drug (placebo or deucrictibant, 20 or 40 mg/day) for 12 weeks of treatment.
“These data validate the mechanism of deucrictibant to provide early and sustained protection from HAE attacks.
By better understanding and addressing these factors, we aspire to make our commitment to ‘pioneering science for patient choice’ a reality.”

Pharvaris Announces Extraordinary Meeting of Shareholders

Retrieved on:

Friday, February 16, 2024

EST, HAE, Hereditary angioedema

ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the extraordinary general meeting of shareholders will take place on Wednesday, March 6, 2024, at 12:00 CST (6:00 a.m. EST).

Key Points:

ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the extraordinary general meeting of shareholders will take place on Wednesday, March 6, 2024, at 12:00 CST (6:00 a.m. EST).
All relevant documents and information relating to the extraordinary general meeting, including the notice and agenda for the extraordinary general meeting, are or will be made available in the “Investors” section of Pharvaris’ website under “Events & Presentations”.
The documents will also be made available on the SEC’s website at www.sec.gov.
Shareholders who wish to attend the meeting should register as described in the notice and agenda for the extraordinary general meeting.

Pharvaris to Present at the WSAAI Annual Meeting 2024

Retrieved on:

Friday, January 26, 2024

HAE, Hereditary angioedema, Treatment, Bradykinin receptor B2, Safety, Abstract, Pharmaceutical industry

ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024, to be held from February 4-8, 2024, at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii.

Key Points:

ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024, to be held from February 4-8, 2024, at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii.
Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
The posters will be made available throughout the conference and on the Investors section of the Pharvaris website at the beginning of the poster session at: https://ir.pharvaris.com/news-events/events-presentations .

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Retrieved on:

Monday, January 22, 2024

Investigational New Drug, Attack, HAE, Hereditary angioedema, IND, Food, FDA, Pharmaceutical industry

We will request an End-of-Phase 2 meeting with the FDA to align on key elements of CHAPTER-3, the anticipated global Phase 3 study of deucrictibant extended-release tablets (PHVS719) for the prophylactic treatment of HAE attacks.”

Key Points:

We will request an End-of-Phase 2 meeting with the FDA to align on key elements of CHAPTER-3, the anticipated global Phase 3 study of deucrictibant extended-release tablets (PHVS719) for the prophylactic treatment of HAE attacks.”
In August 2022, the FDA placed clinical studies of deucrictibant, including CHAPTER-1, on hold.
Pharvaris notified ex-U.S. country-specific regulatory authorities of the clinical hold in the U.S., and the regulatory status of deucrictibant outside the U.S. was not affected.
In June 2023, Pharvaris announced the FDA’s removal of the clinical hold of deucrictibant for the on-demand treatment of HAE in the U.S. following FDA review of data from a preplanned interim analysis of a 26-week rodent toxicology study.
In December 2023, Pharvaris announced positive top-line clinical data from the Phase 2 CHAPTER-1 study of deucrictibant for the prophylactic treatment of HAE attacks.

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

Retrieved on:

Friday, January 5, 2024

“Pharvaris enters the new year having demonstrated deucrictibant’s potential to be the preferred option for both the prevention and treatment of HAE attacks,” said Berndt Modig, Chief Executive Officer of Pharvaris.

Key Points:

“Pharvaris enters the new year having demonstrated deucrictibant’s potential to be the preferred option for both the prevention and treatment of HAE attacks,” said Berndt Modig, Chief Executive Officer of Pharvaris.
The next years will be incredibly important to the company, and Jochen’s continued strategic guidance will be invaluable.”
Anticipated initiation of RAPIDe-3 within 1H2024.
Jochen Knolle, Ph.D., co-founder of Pharvaris, transitions to strategic advisor to the CEO and Executive Committee.
I look forward to continuing to contribute to the strategic transformation of Pharvaris in my new capacity.”
Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

Retrieved on:

Friday, December 8, 2023

Patient, Hereditary angioedema, EST, Conference, BST, Treatment, Capsule, Disease, Data, Attack, Angioedema, EOP, HAE, Pharmaceutical industry

Prof. Markus Magerl, M.D., presented an oral session titled “ Treatment of HAE Attacks with Deucrictibant: RAPIDe-1 Phase 2 Trial Results ” on Friday, December 8, 11:18-11:26 a.m. BST (9:18-9:26 a.m. EST).

Key Points:

Prof. Markus Magerl, M.D., presented an oral session titled “ Treatment of HAE Attacks with Deucrictibant: RAPIDe-1 Phase 2 Trial Results ” on Friday, December 8, 11:18-11:26 a.m. BST (9:18-9:26 a.m. EST).
Prof. Marcus Maurer, M.D., presented a poster titled “ Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant ” on Friday, December 8, 7:00-8:00 p.m. BST (5:00-6:00 p.m. EST).
Primary and post-hoc analyses of the RAPIDe-1 study were conducted to evaluate end of progression (EoP) and symptom relief in response to treatment of HAE attacks with PHVS416.
The onset of symptom relief was achieved at approximately two hours and clinically meaningful improvement within two hours after administration of deucrictibant.